Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01008280 · ClinicalTrials.gov registry record · Phase 4
Baclofen to Reduce Alcohol Use in Veterans With HCV
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT01008280: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT01008280 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01008280, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of the general population and more than 5% of Veterans using VA facilities. As Veterans with HCV have high rates of co-morbid alcohol use disorders that accelerate greatly the liver damage caused by HCV, a safe and effective treatment for alcohol use disorders is needed. Baclofen is a novel treatment for alcohol use disorders that has minimal effect on the liver and may represent a safe and efficacious treatment option for Veterans with HCV and co-morbid alcohol use disorders.
Interventions
- DRUG placebo
- DRUG baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01008280
The ClinicalTrials.gov registry entry for NCT01008280 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01008280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01008280 about?
NCT01008280 is a clinical study titled "Baclofen to Reduce Alcohol Use in Veterans With HCV". Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of the general population and more than 5% of Veterans using VA facilities. As Veterans with HCV have high rates of co-morbid alcohol use disorders that accelerate greatly the liver damage caused by HCV, a saf...
What is the current status of trial NCT01008280?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2010-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01008280?
The interventions under investigation include: placebo (DRUG), baclofen (DRUG).
Who is sponsoring clinical trial NCT01008280?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.